Clinical trialNCT03253575SuspendedObservational

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2

SponsorMitra RxDx, Inc.Enrollment800Adult Solid Tumor

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and different assay developed to test the sensitivity of different cancer types to physician selected therapies (both drugs and/or drug combinations) indicated for the stage and type of cancer for treatment. CANscript™ tests how a patients specific tumor reacts to the therapies being considered by the treating physician. CANscript™ test results have been shown to closely correspond with actual clinical results, providing physicians with information that may help him/her develop a more personalized cancer treatment and care plan based on the patients specific condition. The researchers want to see if CANscript™ test results are helpful in selecting the treatments prescribed and provided. There will be about 800 people taking part in this study, across 5 different tumor types. The study is designed to assess the decision impact of the CANscript™ test results in informing physicians in therapy selection.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Eric Rowinsky, MD
Chief Medical Officer Mitrabiotech
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
University of Colorado School of Medicine-Denver
Aurora, Colorado, United States
Eastern Ct Hematology and Oncology Associates
Norwich, Connecticut, United States
Lynn Cancer Institute
Boca Raton, Florida, United States
Broward Oncology Associates
Fort Lauderdale, Florida, United States
Holy Cross Hospital
Fort Lauderdale, Florida, United States
University of Miami-Sylvester Comprehensive Cancer Center
Miami, Florida, United States
the Center for Gyencologic Oncology
Miramar, Florida, United States
Florida Hospital Cancer Institute
Orlando, Florida, United States
Tallahassee Memorial Cancer Center
Tallahassee, Florida, United States
Memorial Health University Medical Center- Savannah Health Services
Savannah, Georgia, United States
Joliet Oncology Associates
Joliet, Illinois, United States
Edward Elmhurst Healthcare
Naperville, Illinois, United States
Community Hospital
Munster, Indiana, United States
Ochsner Health System
New Orleans, Louisiana, United States
Southcoast Centers for Cancer Care
Fairhaven, Massachusetts, United States
Michigan Center of Medical Research -Mhp
Farmington Hills, Michigan, United States
St John Hospital and Medical Center (great Lakes Cancer Managment Specialists)
Grosse Pointe Woods, Michigan, United States
War Memorial Hematology/oncology
Sault Ste. Marie, Michigan, United States
Mercy Hospital
St Louis, Missouri, United States
University of Rochester/wilmot Cancer Institute
Rochester, New York, United States
Saint Thomas Health
Nashville, Tennessee, United States
Austin Cancer Centers
Austin, Texas, United States
Doctors Hospital at Renaissance-Dhr Health
Edinburg, Texas, United States
University of Texas Medical Branch at Galveston(utmb)
Galveston, Texas, United States
Baylor College of Medicine Hemtology/oncology
Houston, Texas, United States
Houston Methodist Medical Center
Houston, Texas, United States
Oncology Consultants
Houston, Texas, United States
the University of Texas Health Science Center at Houston- Hermann
Houston, Texas, United States
Invesclinic Us Mcallen Oncology
McAllen, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Jul 2017
Primary completion: 31 Jul 2019
Completion: 15 Dec 2019
Last update posted: 8 Apr 2019
Registered enrollment: 800
Registry id: NCT03253575

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.